CFDE Data Portal | Search SELENOOLP

	Label	Description
	SELENOOLP Gene (Entity type)	ENSG00000293509 - selenoprotein O like, pseudogene
	GSE108464 AZ-628 1 v 15 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205714 GSE229013 adenosine 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE101754 FXR1 knockdown NCI-H358 1 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE110709 GSK-J4 5 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 0 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE230865 EYA2 knockdown 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE80098 GSE80366 progesterone 0 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 9 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS

SELENOOLP

ENSG00000293509 - selenoprotein O like, pseudogene

GSE108464 AZ-628 1 v 15 human up

A Gene Set from LINCS

GSE205714 GSE229013 adenosine 3 v 2 human up

A Gene Set from LINCS

GSE101754 FXR1 knockdown NCI-H358 1 v 4 human up

A Gene Set from LINCS

GSE110709 GSK-J4 5 v 4 human dn

A Gene Set from LINCS

GSE100148 EZH2 inhibition 0 v 5 human up

A Gene Set from LINCS

GSE195663 cisplatin 7 v 3 human dn

A Gene Set from LINCS

GSE230865 EYA2 knockdown 3 v 2 human dn

A Gene Set from LINCS

GSE80098 GSE80366 progesterone 0 v 5 human up

A Gene Set from LINCS

GSE100148 EZH2 inhibition 9 v 5 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.